Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report

Martina Spaziante,1 Cristiana Franchi,2 Gloria Taliani,2 Antonio D’Avolio,2 Valeria Pietropaolo,1 Elisa Bilotti,1 Rozenn Esvan,1 and Mario Venditti1

1Department of Health Public and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy, 2Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, Italy, and 3Department of Medical Sciences, University of Turin, Turin, Italy

DOI: 10.1093/ofid/ofz427
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Here we describe a case of a methicillin-resistant coagulase-negative staphylococci prosthetic valve endocarditis in a patient considered not eligible for valve replacement due to high perioperative mortality risk and who did not tolerate oral antibiotic treatment. Under these circumstances, intravenous long-term chronic suppressive antibiotic therapy with dalbavancin, scheduling the doses using the serum bactericidal activity titers, proved to be safe and effective.

Keywords. prosthetic valve endocarditis; long-term chronic suppressive antibiotic therapy; serum bactericidal activity; dalbavancin.

Valve replacement and intravenous targeted antibiotics are the cornerstone of therapy of methicillin-resistant coagulase-negative staphylococci prosthetic valve endocarditis (MRCoNS PVE) [1]. However, occasionally patients refuse or are not eligible for valve replacement due to poor clinical conditions, so that long-term chronic suppressive antibiotic therapy (LTCSAT) remains the only viable treatment option. We here report a unique case of intravenous LTCSAT with dalbavancin, a long-acting lipopeptide antibiotic, in a patient who could not receive oral therapy [2].

CASE REPORT

A 78-year-old man presented to the emergency department for fever lasting 1 month. His medical history included benign prostatic hyperplasia, bowel diverticular disease and Parkinsonism. Seven months before, he underwent aortic valve and tubular ascending aorta replacement by bioprosthetic devices (MagnaEase n.25 and HemaBridge n.10) due to severe aortic valve regurgitation and ascending aorta aneurysm.

On admission, high-resolution computed tomography revealed a bleb of the ascending aorta posterior wall; additionally, hypodense areas, consistent with ischemic lesions, were detected in the right kidney and spleen. Empiric antibiotic therapy with intravenous (i.v.) piperacillin-tazobactam (4.5 g TID) and i.v. daptomycin (500 mg/d) was started. A transesophageal echocardiogram (TEE) displayed 2 vegetations (maximum diameter 14 × 11 mm) on aortic cusps and a periprosthetic abscess, whereas oxacillin-resistant Staphylococcus epidermidis (vancomycin minimal inhibitory concentration [MIC] 1 μg/mL, daptomycin MIC 0.5 μg/mL, rifampicin ≤0.03 μg/mL) and highly penicillin-susceptible Streptococcus mitis (MIC 0.006 μg/mL) were isolated from multiple blood cultures. IE was diagnosed, and targeted therapy with ceftriaxone 2 g BID, 10 mg/kg daptomycin, and 600 mg/d rifampicin was started, with prompt clearance of bacteremia, although rifampin was stopped after 2 days for poor tolerance. Poor clinical conditions and high perioperative risk (EuroSCOREII: 39.07%) were considered contraindications for immediate surgery. Thus, after 7 weeks, initial antimicrobial therapy was discontinued, and the patient was discharged after administration of 1500 mg i.v. dalbavancin (DBV). In vitro DBV susceptibility against the S. epidermidis isolate was not available, so vancomycin susceptibility has been taken into account as a surrogate marker of DBV activity [3].

As reported in Table 1, DBV therapy was scheduled according to serum bactericidal activity (SBA) titers that were measured according to Leighton et al. [4] and performed immediately before each DBV dose. In particular, after day 42 of therapy, it was decided to administer DBV whenever SBA titers ≤1:8 were detected; these circumstances accounted for SBA titers previously reported as resulting in bactericidal cure in infective endocarditis [5]. DBV concentrations have been assessed using a liquid chromatography–mass spectrometry method [6] at 3 treatment time points: days 63, 112, and 133 (Table 1). Overall, our patient received 5 i.v. doses of 1500 mg of DBV, scheduled as shown in Table 1 (days 1, 7, 42, 112, 189).

While on LTCSAT, clinical conditions improved, with progressive disappearance of the 2 vegetative lesions on TEE scans (both originally <10 mm in diameter). On day 42 of DBV LTCSAT, a positron-emission tomography/computed tomography (PET/CT) showed a 9-mm leak at the caudal anastomosis of the aortic tube surrounded by an area of focal uptake, suggesting some residual infection. A follow-up PET/CT
performed on day 140 of DBV LTCSAT showed both reduction of the leak lesion (4-mm diameter) and of the focal uptake. No alterations of renal, liver, and hematopoiesis functions were observed throughout the period of DBV LTCSAT. Currently, the patient is recovered and asymptomatic, and he refuses evaluation for surgery.

**DISCUSSION**

In our case, the 7-week daptomycin plus ceftriaxone regimen without valve replacement could not be a successful therapy for our inoperable case of MRCoNS PVE. The high risk of recurrence due to the patient’s poor general condition and inability to undergo surgery could not be a successful therapy for his inoperable case of MRCoNS PVE. The high risk of recurrence without valve replacement could not be a successful therapy for our inoperable case of MRCoNS PVE. However, the patient refused surgery, and we decided to administer dalbavancin whenever an SBA titer ≤1:8 was detected; these circumstances accounted for through SBA titers previously reported as resulting in bacteriological cure in infective endocarditis [6].

In our case, the 7-week daptomycin plus ceftriaxone regimen without valve replacement could not be a successful therapy for our inoperable case of MRCoNS PVE. The high risk of recurrence without valve replacement could not be a successful therapy for our inoperable case of MRCoNS PVE. However, the patient refused surgery, and we decided to administer dalbavancin whenever an SBA titer ≤1:8 was detected; these circumstances accounted for through SBA titers previously reported as resulting in bacteriological cure in infective endocarditis [6].

In conclusion, notwithstanding the uncertainty surrounding the real efficacy of this therapeutic approach to inoperable gram-positive PVEs.

**References**

1. Habib G, Lancellotti P, Antunes MJ, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2015; 36:3075–128.

2. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the U S A: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013; 75:304–7.

3. Jones RN, Farrell DJ, Flamm RK, et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis 2015; 82(1):73–7.

4. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:940–5.

5. Stratton CW. Serum bactericidal test. Clin Microbiol Rev 1988; 1:19–26.

6. Alebic-Kolbah T, Demers R, Cojocaru L. Dalbavancin: quantification in human plasma and urine by a new improved high performance liquid chromatography-tandem mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:2632–41.

7. Puerta-Alcalde P, Cuervo G, Simonetti AF, et al. PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis. Infect Dis (Lond) 2017; 49:698–701.

8. Kouijzer IJE, Kampschreur LM, Wever PC, et al. The value of 18F-FDG PET/CT in diagnosis and during follow-up in 273 patients with chronic Q fever. J Nucl Med 2018; 59:127–33.
9. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 2019; 380:415–24.
10. Kishor K, Dhasmana N, Kamble SS, Sahu RK. Linezolid induced adverse drug reactions - an update. Curr Drug Metab 2015; 16:553–9.
11. Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 2016; 62:545–51.
12. Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis 2018; 67:795–8.
13. Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis 2018; 6:ofy331.